Induction of allergic inflammation by interleukin-18 in experimental animal models

Immunological Reviews

Volumn 202, Issue , 2004, Pages 115-138

  Tsutsui, Hiroko ^a,b   Yoshimoto, Tomohiro ^a,b   Hayashi, Nobuki ^a,b   Mizutani, Hitoshi ^b,c   Nakanishi, Kenji ^a,b  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

^b JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^c MIE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOTIC PROTEASE ACTIVATING FACTOR 1; BACTERIAL PROTEIN; CASPASE; I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 18; INTERLEUKIN 18 RECEPTOR; INTERLEUKIN 1BETA CONVERTING ENZYME; LIGAND; LIPOPROTEIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MYELOID DIFFERENTIATION FACTOR 88; STAT6 PROTEIN; T LYMPHOCYTE RECEPTOR; TOLL LIKE RECEPTOR; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR;

ALLERGIC DISEASE; ANIMAL MODEL; ANTIGEN SPECIFICITY; ASTHMA; ATOPIC DERMATITIS; BASOPHIL; BRONCHUS HYPERREACTIVITY; CELL ACTIVATION; CELL MATURATION; COMPLEX FORMATION; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DENDRITIC CELL; ENZYME ACTIVATION; EOSINOPHILIA; EXPERIMENTAL ANIMAL; IMMUNE RESPONSE; INFLAMMATION; LYMPHOCYTE DIFFERENTIATION; MAST CELL; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN MOTIF; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; RECEPTOR BINDING; REVIEW; SIGNAL TRANSDUCTION; TH1 CELL; TH2 CELL; TRANSCRIPTION REGULATION; TRANSCRIPTION TERMINATION;

ANIMALS; DISEASE MODELS, ANIMAL; HYPERSENSITIVITY; INFLAMMATION; INTERLEUKIN-18; MEMBRANE GLYCOPROTEINS; RECEPTORS, CELL SURFACE; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS;

EID: 9644266698     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0105-2896.2004.00205.x     Document Type: Review

References (243)

1. Mosmann TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989;7:145-173.
2. Murphy KM, et al. Signaling and transcription in T helper development. Annu Rev Immunol 2000;18:451-494.
3. Afonso LC, Scharton TM, Vieira LQ, Wysocka M, Trinchieri G, Scott P. The adjuvant effect of interleukin-12 in a vaccine against Leishmania major. Science 1994;263:235-237.
4. Reiner SL, Locksley RM. The regulation of immunity to Leishmania major. Annu Rev Immunol 1995;13:151-177.
5. Scharton-Kersten T, Afonso LC, Wysocka M, Trincheri G, Scott P. IL-12 is required for natural killer cell activation and subsequent T helper 1 cell development in experimental leishmaniasis. J Immunol 1995;154:5320-5330.
6. Urban JF, et al. IL-13, IL-4Rα, and stat6 are required for the expulsion of the gastrointestinal nematode parasite Nipostrongylus brasiliensis. Immunity 1998;8:255-264.
7. Finkelman FD, et al. Cytokine regulation of host defense against parasitic gastrointestinal nematodes: lessons from studies with rodent models. Annu Rev Immunol 1997;15:505-533.
8. Wynn TA. IL-13 effector functions. Annu Rev Immunol 2003;21:425-456.
9. Bochner BS, Schleimer RP. Mast cells, basophils, and eosinophils: distinct but overlapping pathways for recruitment. Immunol Rev 2001;179:5-15.
10. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002;105:1135-1143.
11. Bjorkbacka H, et al. Reduced atherosclerosis in MyD88-null mice links elevated serum cholesterol levels to activation f innate immunity signaling pathway. Nat Med 2004;10:416-421.
12. Pawlowski ZS. Ascariasis: host-pathogen biology. Rev Infect Dis 1982;4:806-814.
13. Okamura H, et al. Cloning of a new cytokine that induces IFN-γ production by T cells. Nature 1995;378:88-91.
14. Nakanishi K, Yoshimoto T, Tsutsui H, Okamura H. Interleukin-18 regulates both Th1 and Th2 responses. Annu Rev Immunol 2001;19:423-474.
15. Tsutsui H, Yoshimoto T, Okamura H, Akira S, Nakanishi K. IL-18 and IL-18 receptor knockout mouse. In: Fantuzzi D, ed. Cytokine Knockouts, 2nd edn. Totowa: Humana Press, 2003:303-322.
16. Robinson D, et al. IGIF does not drive Th1 development but synergizes with IL-12 for interferon-gamma production and activates IRAK and NF-κB. Immunity 1997;7:571-581.
17. Yoshimoto T, Okamura H, Tagawa Y, Iwakura Y, Nakanishi K. Interleukin 18 together with interleukin 12 inhibits IgE production by induction of interferon-γ production from activated B cells. Proc Natl Acad Sci USA 1997;94:3948-3953.
18. Dinarello CA, Fantuzzi G. Interleukin-18 and host defense against infection. J Infect Dis 2003;187:S370-S384.
19. Nakanishi K, Yoshimoto T, Tsutsui H, Okamura H. Interleukin-18 is a unique cytokine that stimulates both Th1 and Th2 responses depending on its cytokine milieu. Cytokine Growth Factor Rev 2001;12:53-72.
20. Tsutsui H, Yoshimoto T, Okamura H, Nakanishi K. Interleukin-18. In: Henry HL, Norman AW, eds. Encyclopedia Hormones. New York: Academic Press, 2003:493-500.
21. + T cells, IL-4 and STAT6. Nat Immunol 2000;1:132-137.
22. Konishi H, et al. IL-18 contributes to the spontaneous development of atopic dermatitis-like inflammatory skin lesion independently of IgE/stat6 under specific pathogen-free conditions. Proc Natl Acad Sci USA 2002;99:11340-11345.
23. Sugimoto T, Ishikawa Y, Yoshimoto T, Hayashi N, Fujimoto J, Nakanishi K. IL-18 acts on memory Th1 cells to induce airway inflammation and hyperresponsiveness in a naive host mouse. J Exp Med 2004;199:535-545.
24. Dinarello CA. Targeting interleukin 18 with interleukin 18 binding protein. Ann Rheum Dis 2000;59:i17-i20.
25. Tsutsui H, Adachi K, Seki E, Nakanishi K. Cytokine-induced inflammatory liver injuries. Curr Mol Med 2003;3:545-559.
26. Matsui K, Tsutsui H, Nakanishi K. Pathophysiological roles for IL-18 in inflammatory arthritis. Expert Opin Ther Targets 2003;7:701-724.
27. Janeway CAJ, Medzhitov R. Innate immune recognition. Annu Rev Immunol 2002;20:197-216.
28. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol 2003;21:335-376.
29. Seki E, et al. Critical roles of myeloid differentiation factor 88-dependent proinflammatory cytokine release in early phase clearance of Listeria monocytogenes in mice. J Immunol 2002;169:3863-3868.
30. Edelson BT, Unanue ER. MyD88-dependent but Toll-like receptor 2-independent innate immunity to Listeria: no role for either in macrophage listericidal activity. J Immunol 2002;169:3869-3875.
31. Ulevitch RJ, Tobias PS. Receptor-dependent mechanisms of cell stimulation by bacterial endotoxin. Annu Rev Immunol 1995;13:437-449.
32. Kaisho T, Akira S. Toll-like receptors as adjuvant receptors. Biochem Biophys Acta 2002;1589:1-13.
33. Kaisho T, Takeuchi O, Kawai T, Hoshino K, Akira S. Endotoxin-induced maturation of MyD88-deficient dendritic cells. J Immunol 2001;166:5688-5694.
34. Raetz CRH, Whitfield C. Lipopolysaccharide endotoxins. Annu Rev Biochem 2002;71:634-700.
35. Poltarak A, et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice. Science 1998;282:2085-2088.
36. Qureshi MH, et al. Combined effects of IL-12 and IL-18 on the clinical course and local cytokine production in murine pulmonary infection with Cryptococcus neoformans. Eur J Immunol 1999;29:643-649.
37. Hoshino K, et al. Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: Evidence for TLR4 as the Lps gene product. J Immunol 1999;162:3749-3752.
38. Nagai Y, et al. Essential role of MD-2 in LPS responsiveness and TLR4 distribution. Nat Immunol 2002;3:667-672.
39. Kawasaki K, Akashi S, Shimazu R, Yoshida T, Miyake K, Nishijima M. Mouse Toll-like receptor 4-MD-2 complex mediates lipopolysaccharide-mimetic signal transduction by taxol. J Biol Chem 2000;275:2251-2254.
40. Perera P-Y, et al. CD11b/CD18 acts in concert with CD14 and Toll-like receptor (TLR) 4 to elicit full lipopolysaccharide and taxol-inducible gene expression. J Immunol 2001;166:574-581.
41. Vabulas RM, et al. Endocytosed HSP60s use Toll-like receptor 2 (TLR2) and TLR4 to activate the Toll/Interleukin-1 receptor signaling pathway in innate immune cells. J Biol Chem 2001;276:31332-31339.
42. Ohashi K, Burkart V, Flohé S, Kolb H. Heat shock protein 60 is a putative endogenous ligand of the Toll-like receptor-4 complex. J Immunol 2000;164:558-561.
43. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double stranded RNA and activation of NF-κB by Toll-like receptor 3. Nature 2001;413:732-738.
44. Krieg AM. CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 2002;20:709-760.
45. Hemmi H, et al. A Toll-like receptor recognizes bacterial DNA. Nature 2000;408:740-745.
46. Gewirtz AT, Navas TA, Lyons S, Godowski PJ, Madara JL. Bacterial flagellin activates basolaterally expressed TLR5 to induce epithelial proinflammatory gene expression. J Immunol 2001;167:1882-1885.
47. Hayashi F, et al. The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature 2001;410:1099-1103.
48. Hemmi H, et al. Small antiviral compounds activate immune cells via TLR7 MyD88-dependent signalling pathway. Nat Immunol 2002;3:196-200.
49. Heil F, et al. Species-specific recognition of single-stranded RNA via Toll-like receptor 7 and 8. Science 2004;303:1526-1529.
50. Diebold SS, Kaisho T, Hemmi H, Akira S, Reis e Sousa C. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 2004;303:1529-1531.
51. Zhang D, et al. A Toll-like receptor that prevents infection by uropathogenic bacteria. Science 2004;303:1522-1526.
52. Takeuchi O, et al. Role of Toll-like receptor 1 in mediating immune response to microbial lipoproteins. J Immunol 2002;169:10-14.
53. Takeuchi O, et al. Preferentially the R-stereoisomer of the mycoplasmal lipopeptide macrophage-activating lipopeptide-2 activates immune cells through a Toll-like receptor 2- and MyD88-dependent signaling pathway. J Immunol 2000;164:554-557.
54. Takeuchi O, et al. Discrimination of bacterial lipoproteins by Toll-like receptor 6. Int Immunol 2001;13:933-940.
55. Lien E, et al. Toll-like receptor 2 functions as a pattern recognition receptor for diverse bacterial products. J Biol Chem 1999;274:33419-33425.
56. Ozinsky A, et al. The repertoire for pattern recognition of pathogens by the innate immune system is defined by cooperation between Toll-like receptors. Proc Natl Acad Sci USA 2000;97:13766-13771.
57. Medzhitov R, Preston-Hurburt P, Janeway CAJ. Innate immunity: the virtues of a nonclonal system of recognition. Cell 1998;91:295-298.
58. O'Neill L. The Toll/interleukin-1 receptor domain: a molecular switch for inflammation and host defense. Biochem Sic Trans 2000;28:557-563.
59. Wesche H, Henzel WJ, Shillinglaw W, Li S, Cao Z. MyD88: an adapter that recruits IRAK to the IL-1 receptor complex. Immunity 1997;7:837-847.
60. Cao Z, Henzel WJ, Gao X. IRAK: A kinase associated with the interleukin-1 receptor. Science 1996;271:1128-1131.
61. Li S, Strelow A, Fontana EJ, Weshe H. IRAK-4: A novel member of the IRAK family with the properties of an IRAK-kinase. Proc Natl Acad Sci USA 2002;99:5567-5572.
62. Medvedev AE, Lentschat A, Wahl LM, Golenbock DT, Vogel SN. Dysregulation of LPS-induced Toll-like receptor 4-MyD88 complex formation and IL-1 receptor associated kinase 1 activation in endotoxin-tolerant cells. J Immunol 2002;169:5209-5216.
63. Wang C, Deng L, Hong M, Akkaraju GR, Inoue J, Chen ZJ. TAK1 is a ubiquitin-dependent kinase of MKK and IKK. Nature 2001;412:346-351.
64. Deng L, et al. Activation of the IκB kinase complex by TRAF 6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain. Cell 2000;103:351-361.
65. Adachi O, et al. Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function. Immunity 1998;9:143-150.
66. Kawai T, Adachi O, Ogawa T, Takeda K, Akira S. Unresponsiveness of MyD88-deficient mice to endotoxin. Immunity 1999;11:115-122.
67. Kanakaraj P, et al. Interleukin (IL)-1 receptor-associated kinase (IRAK) requirement for optimal induction of multiple IL-1 signaling pathways and IL-6 production. J Exp Med 1998;187:2073-2079.
68. Kanakaraj P, et al. Defective interleukin (IL)-18-mediated natural killer and T helper cell type 1 responses in IL-1 receptor-associated kinase (IRAK)-deficient mice. J Exp Med 1999;189:1129-1138.
69. Thomas JA, et al. Impaired cytokine signaling in mice lacking the IL-1 receptor-associated kinase. J Immunol 1999;163:978-984.
70. Suzuki N, et al. Severe impairment of interleukin-1 and Toll-like receptor signaling in mice lacking IRAK-4. Nature 2002;416:750-754.
71. Suzuki N, Suzuki S, Yeh W-C. IRAK-4 as the central TIR signaling mediator in innate immunity. Trends Immunol 2002;223:503-506.
72. Suzuki N, et al. IRAK-4 is essential for interleukin-18-mediated natural killer and T helper cell type 1 response. J Immunol 2003;170:4031-4035.
73. Horng T, Barton GM, Medzhitov R. TIRAP: an adapter molecule in the Toll signaling pathway. Nat Immunol 2001;2:835-841.
74. Fitzgerald KA, et al. Mal (MyD88-adaptor-like) is required fro Toll-like receptor-4 signal transduction. Nature 2001;413:78-83.
75. Yamamoto M, et al. Essential role for TIRAP in activation of the signalling cascade shared by TLR2 and TLR4. Nature 2002;420:324-329.
76. Horng T, Barton GM, Flavell RA, Medzhitov R. The adaptor molecule TIRAP provides signalling specificity for Toll-like receptors. Nature 2002;420:329-333.
77. Kawai T, et al. Lipopolysaccharide stimulates the MyD88-independent pathway and results in activation of IFN-γ regulatory factor 3 and the expression of a subset of lipopolysaccharide-inducible genes. J Immunol 2001;167:5887-5894.
78. Sato S, Takeuchi O, Fujita T, Tomizawa H, Takeda K, Akira S. A variety of microbial components induce tolerance to lipopolysaccharide by differentially affecting MyD88-dependent and -independent pathways. Int Immunol 2002;14:783-791.
79. Yamamoto M, et al. A novel Toll/IL-1 receptor domain-containing adapter that preferentially activates the IFN-β promoter in the Toll-like receptor signaling. J Immunol 2002;169:6668-6672.
80. Oshiumi H, Matsumoto M, Funami K, Akazawa T, Seya T. TICAM-1, an adaptor molecule that participates in Toll-like receptor 3-mediated interferon-β induction. Nat Immunol 2003;4:161-167.
81. Yamamoto M, et al. Role of adaptor TRIF in the MyD88-independent Toll-like receptor signaling pathway. Science 2003;301:640-643.
82. Yamamoto M, et al. TRAM is specifically involved in the Toll-like receptor 4-mediated MyD88-independent signaling pathway. Nat Immunol 2003;4:1144-1150.
83. Seki E, et al. LPS-induced IL-18 secretion from murine Kupffer cells independently of MyD88 that is critically involved in induction of production of IL-12 and IL-1β. J Immunol 2001;166:2651-2657.
84. Naik SM, et al. Human keratinocytes constitutively express interleukin-18 and secrete biologically active interleukin-18 after treatment with pro-inflammatory mediators and dinitrochlorobenzene. J Invest Dermatol 1999;113:766-772.
85. Gu Y, et al. Activation of interferon-γ inducing factor mediated by interleukin-1β converting enzyme. Science 1997;275:206-209.
86. Ghayur T, et al. Caspase-1 processes IFN-γ-inducing factor and regulates LPS-induced IFN-γ production. Nature 1997;386:619-623.
87. Alnemri ES, et al. Human ICE/CED-3 protease nomenclature. Cell 1996;87:171.
88. Thornbery NA, et al. A novel heterodimeric cysteine protease is required for interleukin-1β processing in monocytes. Nature 1992;356:768-774.
89. Li P, et al. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 1997;91:479-489.
90. Inohara N, Núñez G. The NOD: a signaling module that regulates apoptosis and host defense against pathogens. Oncogene 2001;20:6473-6481.
91. Zou H, Li Y, Liu X, Wang X. An APAF-1-cytochrome c multimeric complex is a functional apoptosome that activates procaspase-9. J Biol Chem 1999;274:11549-11556.
92. Adrain C, Martin SJ. The mitochondrial apoptosome: a killer unleashed by the cytochrome seas. Trends Biochem Sci 2001;26:390-397.
93. Danial NN, Korsmeyer SJ. Cell death: Critical control points. Cell 2004;116:205-219.
94. Matsumoto J, et al. ASC, a novel 22-kDa protein, aggregates during apoptosis of human promyelocytic leukemia HL-60 cells. J Biol Chem 1999;274:33835-33838.
95. Srinivasula SM, Poyet J-L, Razmara M, Datta P, Zhang Z-J, Alnemri ES. The PYRIN-CARD protein ASC is an activating adaptor for caspase-1. J Biol Chem 2002;277:21119-21122.
96. Wang L, et al. PYPAF7, a novel PYRIN-containing Apaf1-like protein that regulates activation of NF-κB and caspase-1-dependent cytokine processing. J Biol Chem 2002;277:29874-29880.
97. Martinon F, Burns K, Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-1β. Mol Cell 2002;10:417-426.
98. Tschopp J, Martinon F, Burns K. NALPs: a novel protein family involved in inflammation. Nat Rev Immunol 2003;4:95-104.
99. Jin Chae J, et al. Targeted disruption of pyrin, the FMF protein, causes heightened sensitivity to endotoxin and a defect in macrophage apoptosis. Mol Cell 2003;11:591-604.
100. Mariathasan S, et al. Differential activation of the inflammasone by caspase-1 adaptors ASC and Ipaf. Nature 2004;430:213-218.
101. Yamamoto M, et al. ASC is essential for LPS-induced activation of procaspase-1 independently of TLR-associated signal adapter molecules. Genes to Cells 2004; in press.
102. Tsutsui H, et al. Caspase-1-independent, Fas/Fas ligand-mediated IL-18 secretion from macrophages causes acute liver injury in mice. Immunity 1999;11:359-367.
103. Miwa K, Asano M, Horai R, Iwakura Y, Nagata S, Suda T. Caspase-1-independent IL-1β release and inflammation induced by the apoptosis inducer Fas ligand. Nat Med 1998;4:1287-1292.
104. Adachi K, et al. Plasmodium berghei infection in mice induces liver injury by an IL-12- and Toll-like receptor/myeloid differentiation factor 88-dependent mechanism. J Immunol 2001;167:5928-5934.
105. Tsuji NM, et al. Roles of caspase-1 in Listeria infection in mice. Int Immunol 2004;16:335-343.
106. Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol 2001;2:675-680.
107. + T cells in the induction of immunoglobulin E antibodies in response to interleukin-18 treatment of mice. J Exp Med 2003;197:997-1005.
108. Kato Z, et al. The structure and binding mode of interleukin-18. Nat Struct Biol 2003;10:966-971.
109. Tominaga K, et al. IL-12 synergizes with IL-18 or IL-1β for IFN-γ production from human T cells. Int Immunol 2000;12:151-160.
110. Kaser A, Kaser S, Kanekeider NC, Enrich B, Wiedermann CJ, Tilg H. Interleukin-18 attracts plasmacytoid dendritic cells (DC2) and promotes Th1 induction by DC2s through IL-18 receptor expression. Blood 2004;103:648-655.
111. Munder M, Mallo M, Eichmann K, Modolell M. Murine macrophages secrete interferon γ upon combined stimulation with interleukin (IL)-12 and IL-18: a novel pathway of autocrine macrophage activation. J Exp Med 1998;187:2103-2108.
112. Makiishi-Shimobayashi C, et al. Interleukin-18 up-regulates osteoprotegerin expression in stromal/osteoblastic cells. Biochem Biophys Res Commun 2001;281:361-366.
113. Alaaeddine N, Olee T, Hashimoto S, Creighton-Achermann L, Lotz M. Production of the chemokine RANTES by articular chondrocytes and role in cartilage degradation. Arthritis Rheum 2001;44:1633-1643.
114. Leung BP, et al. A role for IL-18 in neutrophil activation. J Immunol 2001;167:2879-2886.
115. Chandrasekar B, et al. Activation of intrinsic and extrinsic pro-apoptotic signaling pathways in interleukin-18-mediated human cardiac endothelial cell death. J Biol Chem 2004.
116. Yang J, Zhu H, Murphy TL, Ouyang W, Murphy KM. IL-18-stimulated GADD45β required in cytokine-induced, but not TCR-induced, IFN-γ production. Nat Immunol 2001;2:157-164.
117. Fornace AJJ, Jackman J, Hollander MC, Hoffman-Liebermann B, Liebermann DA. Genotoxic-stress-response genes and growth-arrest genes, gadd, MyD, and other genes induced by treatments eliciting growth arrest. Ann N Y Acad Sci 1992;663:139-153.
118. Hollander MC, et al. Genomic instability in Gadd45α-deficient mice. Nat Genet 1999;23:176-184.
119. Abdollahi A, Lord KA, Hoffman-Liebermann B, Liebermann DA. Sequence and expression of a cDNA encoding MyD118: a novel myeloid differentiation primary response gene induced by multiple cytokines. Oncogene 1991;6:165-167.
120. Beadling C, Johnson KW, Smith KA. Isolation of interleukin 2-induced immediate-early genes. Proc Natl Acad Sci USA 1993;90:2719-2723.
121. Takekawa M, Saito H. A family of stress-inducible GADD45-like proteins mediate activation of the stress-responsive MTK1/MEKK4/MAPKKK. Cell 1998;95:521-530.
122. Lu B, et al. GADD45γ mediates the activation of the p38 and JNK MAP kinase pathways and cytokine production in effector Th1 cells. Immunity 2001;14:583-590.
123. Lu B, Ferrandino AF, Flavell RA. Gadd45β is important for perpetuating cognate and inflammatory signals in T cells. Nat Immunol 2004;5:38-44.
124. -/- mice through release of interferon-γ. Circ Res 2002;90:e34-e38.
125. Luster AD. Chemokines-chemotactic cytokines that mediate inflammation. N Engl J Med 1998;338:436-445.
126. Wang W, et al. Interleukin-18 enhances the production of interleukin-8 by eosinophils. Eur J Immunol 2001;31:1010-1016.
127. Morel JCM, Park CC, Kumar P, Koch AE. Interleukin-18 induces rheumatoid arthritis synovial fibroblast CXC chemokine production through NF-κB activation. Lab Invest 2001;81:1371-1383.
128. Ruth JH, et al. Role of macrophage inflammatory protein-3α and its ligand CCR6 in rheumatoid arthritis. Lab Invest 2003;83:579-588.
129. Morel JCM, Park CC, Zhu K, Kumar P, Roth JH, Koch AE. Signal transduction pathways involved in rheumatoid arthritis synovial fibroblast IL-18-induced vascular cell adhesion molecule-1 expression. J Biol Chem 2002;277:34679-34691.
130. McInnes IB, Gracie JA, Liew FY. Interleukin-18: a novel cytokine in inflammatory rheumatic disease. Arthritis Rheum 2001;44:1481-1483.
131. Kanal T, et al. Macrophage-derived IL-18-mediated intestinal inflammation in the murine model of Crohn's disease. Gastroenterology 2001;121:875-888.
132. Ten Hove T, et al. Blockade of endogenous IL-18 ameliorates TNSB-induced colitis by decreasing local TNF-α production in mice. Gastroenterology 2001;121:1372-1379.
133. + T cells, but not B cells, mediate colitis in interleukin 10-deficient mice. J Exp Med 1996;184:241-251.
134. Kozaiwa K, et al. Identification of a quantitative trait locus for ileitis in a spontaneous mouse model of Crohn's disease: SAMP1/YitFc. Gastroenterology 2003;125:477-490.
135. Oikawa Y, et al. Systemic administration of IL-18 promotes diabetes development in young nonobese diabetic mice. J Immunol 2003;171:5865-5875.
136. Schott WH, et al. Caspase-1 is not required for type 1 diabetes in the NOD mouse. Diabetes 2004;53:99-104.
137. Blackenberg S, et al. Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina. Circulation 2002;106:24-30.
138. Blankenberg S, et al. Interleukin-18 and the risk of coronary heart disease in European men: The prospective epidemiological study of myocardial infarction (PRIME). Circulation 2003;108:2453-2459.
139. Kretowski A, Kinalska I. Serum levels of interleukin-18 - a potential marker of cardiovascular death - could be determined by genetic predisposition. Circulation 2003;107:e206-e207.
140. Elhage R, et al. Reduced atherosclerosis in interleukin-18 deficient apolipoprotein E-knockout mice. Cardiovasc Res 2003;59:234-240.
141. Okamoto I, et al. IL-18 prevents the development of chronic graft-versus-host disease in mice. J Immunol 2000;164:6067-6074.
142. Reddy P, et al. Interleukin-18 regulates acute graft-versus-host disease by enhancing Fas-mediated donor T cell apoptosis. J Exp Med 2001;194:1433-1440.
143. Fujimori Y, et al. Elevated interleukin (IL)-18 levels during acute graft-versus-host disease after allogeneic bone marrow transplantation. Br J Haematol 2000;109:652-657.
144. Fujimori Y, et al. Increased expression of interleukin 18 receptor on T lymphocytes in patients with acute graft-versus-host disease after allogeneic bone marrow transplantation. J Interferon Cytokine Res 2002;22:751-754.
145. Itoi H, et al. Fas ligand-induced caspase-1-dependent accumulation of interleukin (IL)-18 in mice with acute graft-versus-host disease. Blood 2001;98:235-237.
146. + T cells during acute graft-versus disease in mice. J Interferon Cytokine Res 2004;24:291-296.
147. Yamanaka K, et al. Skin-specific caspase-1 transgenic mice show cutaneous apoptosis and pre-endotoxin shock condition with a high serum level of IL-18. J Immunol 2000;165:997-1003.
148. Hoshino T, et al. IL-18-transgenic mice: In vivo evidence of a broad role for IL-18 in modulating immune function. J Immunol 2001;166:7014-7018.
149. + T cells. Eur J Immunol 2000;30:1998-2006.
150. Armitage RJ, et al. Molecular and biological characterization of a murine ligand for CD40. Nature 1992;357:80-82.
151. Kronenberg M, Gapin L. The unconventional lifestyle of NKT cells. Nat Rev Immunol 2002;2:557-568.
152. Taniguchi M, Harada M, Kojo S, Nakayama T, Wakao H. The regulatory role of Vα14 NKT cells in innate and acquired immune response. Annu Rev Immunol 2003;21:483-513.
153. Le Gros G, Ben-Sasson SZ, Seder R, Finkelman FD, Paul WE. Generation of interleukin 4 (IL-4)-producing cells in vivo and in vitro: IL-2 and IL-4 are required for in vitro generation of IL-4-producing cells. J Exp Med 1990;172:921-929.
154. Zhu J, Cote-Sierra J, Guo L, Paul WE. Stat5 activation plays a critical role in Th2 differentiation. Immunity 2003;19:739-748.
155. Cote-Sierra J, et al. Interleukin 2 plays a central role in Th2 differentiation. Proc Natl Acad Sci USA 2004;101:3880-3885.
156. Zhu J, et al. Growth factor independent-1 induced by IL-4 regulates Th2 cell proliferation. Immunity 2002;16:733-744.
157. Flaut M, Pierce JH, Watson CJ, Hanley-Hyde J, Nordan RP, Paul WE. Mast cell lines produce lymphocytes in response to cross-linkage of Fcε RI or to calcium ionophores. Nature 1989;339:64-67.
158. + cells. Adv Immunol 1993;53:1-29.
159. Weiss DL, Brown MA. Regulation of IL-4 production in mast cells: a paradigm for cell-type-specific gene expression. Immunol Rev 2001;179:35-47.
160. Yoshimoto T, et al. IL-18, although anti-allergic when administered with IL-12, stimulates IL-4 and histamine release by basophils. Proc Natl Acad Sci USA 1999;96:13962-13966.
161. Unanue ER. Studies in listeriosis show the strong symbiosis between the innate cellular system and the T-cell response. Immunol Rev 1997;158:11-25.
162. Murphy KM. T lymphocyte differentiation in the periphery. Curr Opin Immunol 1998;10:226-232.
163. Helmby H, Takeda K, Akira S, Grencis RK. Interleukin (IL)-18 promotes the development of chronic gastrointestinal helminth infection by downregulating IL-13. J Exp Med 2001;194:355-364.
164. Helmby H, Grencis RK. IL-18 regulates intestinal mastocytosis and Th2 cytokine production independently of IFN-γ during Trichinella spiralis infection. J Immunol 2002;169:2553-2560.
165. +T cells in autoimmune diabetes through the use of TCR transgenic mice. Immunol Rev 1999;169:55-56.
166. Saini SS, McGlashan D. How IgE upregulates the allergic response. Curr Opin Immunol 2002;14:694-697.
167. Temann U-A, Geba GP, Rankin JA, Flavell RA. Expression of interleukin 9 in the lungs of transgenic mice causes airway inflammation, mast cell hyperplasia, and bronchial hyperresponsiveness. J Exp Med 1998;188:1307-1320.
168. Wills-Karp M, et al. Interleukin-13: Central mediator of allergic asthma. Science 1998;282:2258-2261.
169. Grünig G, et al. Requirement for IL-13 independently of IL-4 in experimental asthma. Science 1998;282:2261-2263.
170. Louahed J, et al. Interleukin-9 upregulates mucus expression in the airways. Am J Respir Cell Mol Biol 2000;22:649-656.
171. Kuperman DA, et al. Direct effects of interleukin-13 on epithelial cells cause airway hyperreactivity and mucus overproduction in asthma. Nat Med 2002;8:885-889.
172. Hultner L, et al. Mast cell growth-enhancing activity (MEA) is structurally related and functionally identical to the novel mouse T cell growth factor P40/TCGFIII (interleukin 9). Eur J Immunol 1990;20:1413-1416.
173. Tliba O, et al. IL-13 enhances agonist-evoked calcium signals and contractile responses in airway smooth muscle. Br J Pharmacol 2003;140:1159.
174. Fallon PG, Emson CL, Smith P, McKenzie ANJ. IL-13 overexpression predisposes to anaphylaxis following antigen sensitization. J Immunol 2001;166:2712-2717.
175. Temann U-A, Ray P, Flavell RA. Pulmonary overexpression of IL-9 induces Th2 cytokine expression, leading to immune pathology. J Clin Invest 2002;109:29-39.
176. Oppenheim JJ, Zachariae COC, Mukaida N, Matsushima K. Properties of the novel proinflammatory supergene 'Intercrine' cytokine family. Annu Rev Immunol 1991;9:617-648.
177. Ordonez CL, Shaughnessy TE, Matthay MA, Fahy JV. Increased neutrophil numbers and IL-18 levels in airway secretions in acute severe asthma: Clinical and biologic significance. Am J Respir Crit Care Med 2000;161:1185-1190.
178. Corrigan CJ, Kay AB. CD4 T-lymphocyte activation in acute severe asthma: relationship to disease severity and atopic status. Am Rev Respir Dis 1990;141:970-977.
179. Cembrzynska-Nowak M, Szklarz E, Inglot AD, Teodorczyk-Injeyan JA. Elevated release of tumor necrosis factor-alpha and interferon-gamma by bronchoalveolar leukocytes from patients with bronchial asthma. Am Rev Respir Dis 1993;147:291-295.
180. Zheng W, Flavell RA. The transcription factor GATA-3 is necessary and sufficient for Th2 cytokine gene expression in CD4 T cells. Cell 1997;89:587-596.
181. Szabo SJ, Kim ST, Costa GL, Zhang X, Fathman CG, Glimcher LH. A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell 2000;100:655-669.
182. Loots GG, et al. Identification of a coordinate regulator of interleukins 4, 13, and 5 by cross-species sequence comparisons. Science 2000;288:136-140.
183. Solymar DC, Agarwal S, Bassing CH, Alt FW, Rao A. A-3′ enhancer in the IL-4 gene regulates cytokine production by Th2 cells and mast cells. Immunity 2002;17:41.
184. Rudikoff D, Lebwohl M. Atopic dermatitis. Lancet 1998;351:1715-1721.
185. Akdis CA, Akdis M, Trautmann A, Blaser K. Immune regulation in atopic dermatitis. Curr Opin Immunol 2000;12:641-646.
186. Leung DYM, Boguniewicz M, Howell MD, Nomura I, Hamid QA. New insights into atopic dermatitis. J Clin Invest 2004;113:651-657.
187. Wills-Karp M. Immunologic basis of antigen-induced airway hyperresponsiveness. Ann Rev Immunol 1999;17:255-281.
188. Busse WW, Lemanske RFJ. Asthma. N Engl J Med 2001;344:350-362.
189. Lemanske RF, Busse WW. Asthma. J Allergy Clin Immunol 2003;111:S502-S519.
190. Elias JA, Geun Lee C, Zheng T, Ma B, Homer RJ, Zhu Z. New insights into the pathogenesis of asthma. J Clin Invest 2003;111:291-297.
191. Novak N, Bieber T. Allergic and nonallergic forms of atopic dermatitis. J Allergy Clin Immunol 2003;112:252-262.
192. Umetsu DT, McIntire JJ, Akbari O, Macaubas C, DeKruyff RH. Asthma: an epidemic of dysregulated immunity. Nat Immunol 2002;3:715-720.
193. McIntire JJ, et al. Hepatitis A virus link to atopic disease. Nature 2003;425:576.
194. Grewe M, et al. A role for Th1 and Th2 cells in the immunopathogenesis of atopic dermatitis. Immunol Today 1998;19:359-361.
195. Hotzman MJ, Sampath D, Castro M, Look DC, Jayaraman S. The one-two of T helper cells: does interferon-g knockout the Th2 hypothesis for asthma? Am J Respir Cell Mol Biol 1996;14:316-318.
196. Krug N, et al. T-cell cytokine profile evaluated at the single cell level in BAL and blood in allergic asthma. Am J Respir Cell Mol Biol 1996;14:319-326.
197. Dahl ME, Dabbagh K, Liggit D, Kim S, Lewis DB. Viral-induced T helper type 1 responses enhance allergic disease by effects on lung dendritic cells. Nat Immunol 2004;5:337-343.
198. Akdis CA, et al. T cells and T cell-derived cytokines as pathogenic factors in the nonallergic form of atopic dermatitis. J Invest Dermatol 1999;113:628-634.
199. Klunker S, et al. A second step of chemotaxis after transendothelial migration: Keratinocytes undergoing apoptosis release IFN-γ-inducible protein 10, monokine induced by IFN-γ, and IFN-γ-inducible α-chemoattractant for T cell chemotaxic toward epidermis in atopic dermatitis. J Immunol 2003;171:1078-1084.
200. Blauvelt A, Hwang ST, Udey MC. Allergic and immunologic diseases in the skin. J Allergy Clin Immunol 2003;111: S560-S570.
201. Leung DYM. Atopic dermatitis: the skin as a window into the pathogenesis of chronic allergic diseases. J Allergy Clin Immunol 1995;96:302-318.
202. Leung DYM. Pathogenesis of atopic dermatitis. J Allergy Clin Immunol 1999;104:S99-S108.
203. Spergel JM, Mizoguchi E, Brewer JP, Martin TR, Bhan AK, Geha RS. Epicutaneous sensitization with protein antigen induces localized allergic dermatitis and hyperresponsiveness to methacholine after single exposure to aerosolized antigen in mice. J Clin Invest 1998;101:1614-1622.
204. Spergel JM, Mizoguchi E, Oettgen H, Bhan AK, Geha RS. Roles of Th1 and Th2 cytokines in a murine model of allergic dermatitis. J Clin Invest 1999;103:1103-1111.
205. Matsuda H, et al. Development of atopic dermatitis-like skin lesion with IgE hyperproduction in NC/Nga mice. Int Immunol 1996;9:461-466.
206. Yagi R, Nagai H, Iigo Y, Akimoto T, Arai T, Kubo M. Development of atopic dermatitis-like skin lesions in STAT6-deficient NC/Nga mice. J Immunol 2002;168:2020-2027.
207. Tanaka T, et al. Interleukin-18 is elevated in the sera from patients with atopic dermatitis and from atopic dermatitis model mice, NC/Nga. Int Arch Allergy Immunol 2001;125:236-240.
208. Higa S, et al. Administration of anti-interleukin 18 antibody fails to inhibit development of dermatitis in atopic dermatitis-model mice NC/Nga. Br J Dermatol 2003;149:39-45.
209. Koro O, Furutani K, Hide M, Yamada S, Yamamoto S. Chemical mediators in atopic dermatitis: involvement of leukotriene B4 released by a type I allergic reaction in the pathogenesis of atopic dermatitis. J Allergy Clin Immunol 1999;103:663-670.
210. Broide D, Sriramanto P. Eosinophil trafficking to sites of allergic inflammation. Immunol Rev 2001;179:163-172.
211. Nakano H, et al. Persistent secretion of IL-18 in the skin contributes to IgE response in mice. Int Immunol 2003;15:611-621.
212. El-Mezzein RE, Matsumoto T, Nomiyama H, Miike T. Increased secretion of IL-18 in vitro by peripheral blood mononuclear cells of patients with bronchial asthma and atopic dermatitis. J Clin Immunol 2001;126:193-198.
213. Yoshizawa Y, Nomaguchi H, Izaki S, Kitamura K. Serum cytokine levels in atopic dermatitis. Clin Exp Dermatol 2002;27:225-229.
214. Higashi N, Gesser B, Kawana S, Thestrup-Pedersen K. Expression of IL-18 mRNA and secretion of IL-18 are reduced in monocytes from patients with atopic dermatitis. J Allergy Clin Immunol 2001;108:607-614.
215. Davies DE, Wicks J, Powell RM, Puddicombe SM, Holgate ST. Airway remodeling in asthma: new insights. J Allergy Clin Immunol 2003;111:215-225.
216. Zhang D-H, et al. Inhibition of allergic inflammation in a murine model of asthma by expression of a dominant-negative mutant of GATA-3. Immunity 1999;11:473-482.
217. Finotto S, et al. Treatment of allergic airway inflammation and hyperresponsiveness by antisense-induced local blockade of GATA-3 expression. J Exp Med 2001;193:1247-1260.
218. Barnes PJ. Therapeutic strategies for allergic diseases. Nature 1999;402:31-38.
219. Huang T-J, et al. Allergen-specific TH1 cells counteract efferent Th2 cell-dependent bronchial hyperresponsiveness and eosinophilic inflammation partly via IFN-γ. J Immunol 2001;166:207-217.
220. Randolph DA, Carruthers CJL, Szabo SJ, Murphy KM, Chaplin DD. Modulation of airway inflammation by passive transfer of allergen-specific Th1 and Th2 cells in a mouse model of asthma. J Immunol 1999;162:2375-2383.
221. Hansen G, Berry G, DeKruyff RH, Umetsu DT. Allergen-specific Th1 cells fail to counterbalance Th2 cell-induced airway hyperreactivity but cause severe airway inflammation. J Clin Invest 1999;103:175-183.
222. Ford JG, et al. IL-13 and IFN-γ: interactions in lung inflammation. J Immunol 2001;167:1769-1777.
223. Cameron LA, et al. Airway epithelium expresses interleukin-18. Eur Respir J 1999;14:553-559.
224. Monick MM, et al. Respiratory syncytial virus up-regulates TLR4 and sensitizes airway epithelial cells to endotoxin. J Biol Chem 2003;278:53035-53044.
225. Guillot L, et al. Response of human pulmonary epithelial cells to lipopolysaccharide involves Toll-like receptor 4 (TLR4)-dependent signaling pathways: evidence for an intracellular compartmentalization of TLR4. J Biol Chem 2004;279:2717-2718.
226. Wong CK, et al. Proinflammatory cytokines (IL-17, IL-6, IL-18 and IL-12) and Th cytokines (IFN-g, IL-4, IL-10 and IL-13) in patients with allergic asthma. Clin Exp Immunol 2001;125:177-183.
227. Tanaka H, et al. IL-18 might reflect disease activity in mild and moderate asthma exacerbation. J Allergy Clin Immunol 2001;107:331-336.
228. Higa S, et al. Association between interleukin-18 gene polymorphism 105A/C and asthma. Clin Exp Allergy 2003;33:1097-1102.
229. Verhaeghe B, et al. Up-regulation of IL-18 in allergic rhinitis. Allergy 2002;57:825-830.
230. Kruse S, et al. Polymorphisms in the IL-18 gene are associated with specific sensitization to common allergens and allergic rhinitis. J Allergy Clin Immunol 2003;111:117-122.
231. O'Neill LA, Dinarello CA. The IL-1 receptor/toll-like receptor superfamily: critical receptors for inflammation and host defense. Immunol Today 2000;21:206-209.
232. Akira S. The role of IL-18 in innate immunity. Curr Opin Immunol 2000;12:59-63.
233. Takeuchi O, Akira S. Genetic approaches to the study of Toll-like receptor function. Microbes Infect 2002;4:887-895.
234. Gomez-Gomez L, Boller T. Flagellin perception: a paradigm for innate immunity. Trends Plant Sci 2002;7:251-256.
235. Lomaga MA, et al. TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. Genes Dev 1999;13:1015-1024.
236. Takaesu G, et al. TAB2, a novel adaptor protein, mediates activation of TAK1 MAPKKK by linking TAK1 to TRAF6 in the IL-1 signal transduction pathway. Mol Cell 2000;5:649-658.
237. Takaesu G, Ninomiya T, Suji J, et al. Interleukin-1 (IL-1) receptor-associated kinase leads to activation of TAK1 by inducing TAB2 translocation in IL-1 signaling pathway. Mol Cell Biol 2001;21:2475-2484.
238. Rich T, Allen RL, Wyllie AH. Defying death after DNA damage. Nature 2000;407:777-783.
239. Hyodo Y, et al. IL-18 up-regulates perforin-mediated NK activity without increasing perform messenger RNA expression by binding to constitutively expressed IL-18 receptor. J Immunol 1999;162:1662-1668.
240. Kaisho T, et al. Impairment of natural killer cytotoxic activity and interferon gamma production in CCAAT/enhancer binding protein gamma-deficient mice. J Exp Med 1999;190:1573-1582.
241. Shimoda K, et al. Partial impairment of interleukin-12 (IL-12) and IL-18 signaling in Tyk2-deficient mice. Blood 2002;99:2094-2099.
242. Yoshimoto T, et al. IL-12 up-regulates IL-18 receptor expression on T cells, Th1 cells, and B cells: synergism with IL-18 for IFN-γ production. J Immunol 1998;161:3400-3407.
243. + effector T cells is differentially regulated by IL-18 and IL-12. J Immunol 1999;162:3202-3211.